In breast cancer, recent studies have shown that TAK1 plays important roles in mediating the effects of CCN619, TRAF420, UBC1321, and mir-892b22 on tumor progression and metastasis, and that targeting TAK1 enhances doxorubicin (DOXO)-mediated apoptosis and reduces invasive behavior23, 24. This evidence concerns the gene MAP3K7 and breast cancer.